Salveen Richter

Why Intellia Therapeutics Stock Is Soaring Today

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine

After FDA Rejects Acadia Dementia Drug, Analysts Lament Lack Of Near-term Stock Drivers

Moderna Analyst Says Biotech Has 'First-To-Market' Potential For Coronavirus Vaccine

Goldman Sachs Steps To The Sidelines On Crispr Therapeutics

Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts

Goldman Sachs Steps To The Sidelines On Crispr Therapeutics

Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts

Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

Goldman Sachs: Madrigal Pharma Has Blockbuster Potential In Liver, Cholesterol Treatments

Salveen Richter Recent News

Goldman Sachs Gets Firm On Solid Biosciences

5 Weed Stocks To Watch In 2018

3 Key Questions For Denali Therapeutics Investors

Spark Therapeutics Lacks Catalysts, Says Goldman Sachs

Goldman Sachs Sees 40% Upside In GW Pharmaceuticals

Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure

What To Expect From GW Pharma's Upcoming Round Of Presentations

Bluebird's Gene Therapy Is Firing On All Cylinders

Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook

GW Pharma Set To Fly High: Goldman Sachs Starts Coverage At Buy, Sees 42% Upside

Seattle Genetics No Longer On Goldman Sachs' Sell List

Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List

Atara Biotherapeutics Has 25% Downside

Bluebird Heading Into 'Catalyst-Rich' Second Half Of The Year

Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Clear Skies For Bluebird Bio To Enter A New Inflection Point

Goldman Sachs Still Bullish On BioMarin Pipeline Despite Kyndrisa Pullout

3 Reasons Goldman Sachs Still Neutral On Intercept Pharma

Bluebird Bio's LentiD 'Hits The Mark'

Goldman Is Buying: Bluebird Bio Off To 'Flying Start'

Goldman On Biotech: Buy Sage, Sell Acorda, Neutral On Dimension

Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Avalanche Biotechnologies Buried By Disappointing Data, Downgrades